Brigit Biofarmaka Teknologi Tbk. vs Reksa Dana Indeks KISI IDX Value30 ETF — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp254 (market cap 172.82B, 592.2K 24h volume), while Reksa Dana Indeks KISI IDX Value30 ETF trades at Rp550 (market cap 8.69B, 500 24h volume). The key difference: Brigit Biofarmaka Teknologi Tbk. is far larger — about 19.9× Reksa Dana Indeks KISI IDX Value30 ETF's market cap, and Brigit Biofarmaka Teknologi Tbk. is more actively traded (592.2K versus 500). Which is the better fit depends on your goals.
| OBAT | XKIV | |
|---|---|---|
Market Cap | 172.82B | 8.69B |
Volume | 592.2K | 500 |
Lot | 5.92K | 5 |
Turnover | 147.05M | 275K |
Average Price | 248.31 | 550 |
Value | 147.05M | 275K |
Indicative Equilibrium Price | 254 | — |
Indicative Equilibrium Volume | 10 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →